Skip to content

Narcís Cardoner

5 papers in the library · 19 citations · publishing 2023-2026

Papers

Sort Most recent Most cited

GH001 vs Placebo in Patients With Treatment-Resistant Depression

JAMA Psychiatry March 25, 2026 Wiesław Jerzy Cubała, Malek Bajbouj, Michael Bauer et al. 3 citations

Importance: Few pharmacotherapies are approved for treatment-resistant depression, and many patients do not achieve remission following treatment with those therapies. Objective: To examine the efficacy and safety of single-day treatment with a synthetic formulation of inhaled mebufotenin (GH001) vs placebo in patients with treatment-resistant depression. Design, Setting, and Participants: This...

Clinical and Neuroimaging Effects of Mindfulness-Based Cognitive Therapy for Symptomatic Obsessive-Compulsive Disorder Patients after First-Line Treatments: A Randomised Controlled Trial.

Psychotherapy and Psychosomatics 2026 Maria Serra-Blasco, Neus Miquel-Giner, Muriel Vicent-Gil et al.

Introduction: Obsessive-compulsive disorder (OCD) is a chronic condition where many patients remain symptomatic despite first-line treatments such as cognitive behavioural therapy and selective serotonin reuptake inhibitors. This randomised controlled trial evaluated mindfulness-based cognitive therapy (MBCT) efficacy as an augmentation strategy and its impact on brain functional connectivity....

Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial.

The British journal of psychiatry : the journal of mental science February 1, 2025 Allan H. Young, Pierre-Michel Llorca, Andrea Fagiolini et al. 7 citations

In patients with treatment resistant depression (TRD), the ESCAPE-TRD study showed esketamine nasal spray was superior to quetiapine extended release. To determine the robustness of the ESCAPE-TRD results and confirm the superiority of esketamine nasal spray over quetiapine extended release. ESCAPE-TRD was a randomised, open-label, rater-blinded, active-controlled phase IIIb trial. Patients had...

Mindfulness-based cognitive therapy neurobiology in treatment-resistant obsessive-compulsive disorder: A domain-related resting-state networks approach.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology May 1, 2024 Víctor De la Peña-arteaga, Marta Cano, Daniel Porta-Casteràs et al. 5 citations

Mindfulness-based cognitive therapy (MBCT) stands out as a promising augmentation psychological therapy for patients with obsessive-compulsive disorder (OCD). To identify potential predictive and response biomarkers, this study examines the relationship between clinical domains and resting-state network connectivity in OCD patients undergoing a 3-month MBCT programme. Twelve OCD patients...

Efficacy and fMRI-based response predictors to mindfulness-based cognitive therapy in obsessive-compulsive disorder: Study protocol for a randomised clinical trial.

Revista de psiquiatria y salud mental 2023 Neus Miquel-Giner, Muriel Vicent-Gil, Ignacio Martínez-zalacaín et al. 4 citations

Around 40-50% of patients with obsessive-compulsive disorder (OCD) suffer from obsessions and compulsions after receiving first-line treatments. Mindfulness-based cognitive therapy (MBCT) has been proposed as a reasonable augmentation strategy for OCD. MBCT trains to decentre from distressful thoughts and emotions by focusing on them voluntarily and with consciousness. This practice develops...